Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer

9 May 2020

Abstract excerpt

Although there are molecularly distinct subtypes of prostate cancer, no molecular classification system is used clinically. The ribonucleotide reductase small subunit M2 (RRM2) gene plays an oncogenic role in many cancers. Our previous study elucidated comprehensive molecular mechanisms of RRM2 in prostate cancer (PC). Given the potent functions of RRM2, we set out to determine whether the RRM2 signature can be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Lipids, and Metabolism
Share to Ferroptosis and cancer prognosis
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32385899
DOI: 10.1002/1878-0261.12706

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancerPMID 32385899Read ↗

A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2)Semantic proximity Read ↗

Comprehensive Landscape of RRM2 with Immune Infiltration in Pan-CancerSemantic proximity Read ↗

A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumorsSemantic proximity Read ↗

Tumor suppressor role of RBM22 in prostate cancer acting as a dual-factor regulating alternative splicing and transcription of key oncogenic genesSemantic proximity Read ↗

lncRNA MAGI2-AS3 suppresses castration-resistant prostate cancer proliferation and migration via the miR-106a-5p/RAB31 axisSemantic proximity Read ↗

LNCaP Atlas: Gene expression associated with in vivoprogression to castration-recurrent prostate cancerSemantic proximity Read ↗

MicroRNA-regulated transcriptome analysis identifies four major subtypes with prognostic and therapeutic implications in prostate cancerSemantic proximity Read ↗

Unveiling the NEFH+ malignant cell subtype: Insights from single-cell RNA sequencing in prostate cancer progression and tumor microenvironment interactionsSemantic proximity Read ↗

LncRNA SNHG4 promotes prostate cancer cell survival and resistance to enzalutamide through a let-7a/RREB1 positive feedback loop and a ceRNA networkSemantic proximity Read ↗

An anti-androgen resistance-related gene signature acts as a prognostic marker and increases enzalutamide efficacy via PLK1 inhibition in prostate cancerSemantic proximity Read ↗

RNA modification Regulators' Co-Expression Score (RMRCoeS) predicts biochemical recurrence and therapy response in prostate cancer: A multi-omics and experimental validation study.Semantic proximity Read ↗

Independent prognostic implications of RRM2 in lung adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.